We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

2 hedge funds and large institutions have $63K invested in Loncar China BioPharma ETF in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $51K → $63K (+$12K)

0% more funds holding

Funds holding: 2 → 2 (0)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$48K – – –
PNC Financial Services Group
2
PNC Financial Services Group
Pennsylvania
$15K – – –

CHNA Hedge Fund Activity: Q1 2019 in Review

2 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q1 2019, worth a combined $63K — up 24% from $51K a quarter earlier.

Fund positioning in CHNA was balanced in Q1 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $63K of Loncar China BioPharma ETF stock for Q1 2019, up 24% quarter-over-quarter.
  • 0 funds opened new Loncar China BioPharma ETF positions in Q1 2019 and 0 closed out.

Based on aggregated 13F filings for Q1 2019.